<SEC-DOCUMENT>0001062993-16-010415.txt : 20160706
<SEC-HEADER>0001062993-16-010415.hdr.sgml : 20160706
<ACCEPTANCE-DATETIME>20160706143824
ACCESSION NUMBER:		0001062993-16-010415
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20160706
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160706
DATE AS OF CHANGE:		20160706

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lexaria Bioscience Corp.
		CENTRAL INDEX KEY:			0001348362
		STANDARD INDUSTRIAL CLASSIFICATION:	METAL MINING [1000]
		IRS NUMBER:				202000871
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52138
		FILM NUMBER:		161753428

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 950, 1130 WEST PENDER STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6E 4A4
		BUSINESS PHONE:		604-602-1675

	MAIL ADDRESS:	
		STREET 1:		SUITE 950, 1130 WEST PENDER STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6E 4A4

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXARIA CORP.
		DATE OF NAME CHANGE:	20080229

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Lexaria Corp.
		DATE OF NAME CHANGE:	20051229
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp. - Form 8-K - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B><FONT size=5>UNITED STATES</FONT></B><BR><B><FONT
size=5>SECURITIES AND EXCHANGE COMMISSION</FONT></B><BR>Washington, D.C. 20549
</P>
<P align=center><B><FONT size=5>FORM 8-K </FONT></B></P>
<P align=center><B>CURRENT REPORT </B></P>
<P align=center>Pursuant to Section 13 OR 15(d) of the Securities Exchange Act
of 1934 </P>
<P align=center>Date of Report (Date of earliest event reported) <B><U>July 5,
2016</U></B></P>
<P align=center><B><U><FONT size=5>LEXARIA BIOSCIENCE CORP.</FONT></U></B><B>
</B><BR>(Exact name of registrant as specified in its charter) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><B><U>Nevada </U></B></TD>
    <TD align=center width="33%"><B><U>000-52138 </U></B></TD>
    <TD align=center width="33%"><B><U>20-2000871 </U></B></TD></TR>
  <TR vAlign=top>
    <TD align=center>(State or other jurisdiction of </TD>
    <TD align=center width="33%">(Commission File Number) </TD>
    <TD align=center width="33%">(IRS Employer </TD></TR>
  <TR vAlign=top>
    <TD align=center>incorporation) </TD>
    <TD align=center width="33%">&nbsp; </TD>
    <TD align=center width="33%">Identification No.) </TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center width="50%"><B><U>#950 &#150; 1130 West Pender Street, Vancouver, BC
      Canada&nbsp;</U></B></TD>
    <TD align=center width="50%"><B><U>V6E 4A4 </U></B></TD>
  </TR>
  <TR vAlign=top>
    <TD align=center width="50%">(Address of principal executive offices) </TD>
    <TD align=center width="50%">(Zip Code) </TD>
  </TR>
  <TR>
    <TD align="center" width="50%">&nbsp; </TD>
    <TD width="50%" align="center">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=center width="50%">Registrant&#146;s telephone number, including area code </TD>
    <TD align=center width="50%"><B><U>(604) 602-1675
</U></B></TD>
  </TR></TABLE>
<P align=center><B><U>LEXARIA CORP.</U> </B><BR>(Former name or former
address, if changed since last report.) <BR></P>
<P align=justify>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</P>
<P align=justify>[&nbsp;&nbsp; ]&nbsp; Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)<BR>[&nbsp;&nbsp; ]&nbsp;&nbsp;
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a -12)<BR>[&nbsp;&nbsp; ]&nbsp;&nbsp; Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d
-2(b))<BR>[&nbsp;&nbsp; ]&nbsp;&nbsp; Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))<BR></P>
<P align=justify><B>Item 7.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Regulation FD Disclosure </B></P>
<P align=justify>A copy of the news release announcing our intention to complete
an equity financing of US$300,000 is filed as exhibit 99.1 to this current
report and is hereby incorporated by reference. </P>
<P align=justify><B>Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Financial Statements and Exhibits </B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><a href="exhibit99-1.htm">99.1 </a></TD>
    <TD align=left width="90%" bgColor=#eeeeee ><a href="exhibit99-1.htm">Press Release
      dated July 5, 2016 </a></TD>
  </TR></TABLE>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_2></A>
<P align=center>- 2 - </P>
<P align=center><B>SIGNATURES </B></P>
<P align=justify>Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left><B>LEXARIA BIOSCIENCE CORP.</B> </TD>
    <TD align=left width="50%" >&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="50%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><I>/s/ Chris
      Bunka</I> </TD>
    <TD align=left width="50%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Chris Bunka</B> </TD>
    <TD align=left width="50%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>CEO, Principal Executive Officer </TD>
    <TD align=left width="50%" >&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="50%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Date:&nbsp;&nbsp;&nbsp; July 5, 2016 </TD>
    <TD align=left width="50%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="50%" >&nbsp;</TD></TR></TABLE>
<hr noshade="noshade" align="center" width="100%" size="5" color="black" />
<BR>
</BODY>

</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<title>Lexaria Bioscience Corp. - Form 8-K - Filed by newsfilecorp.com</title>
</HEAD>

<BODY bgcolor="#FFFFFF" style="font-size: 10pt;">
<HR noshade align="center" width=100% size=3 color="black">

<a name="page_1" id="page_3"></a>
<p align="right">Exhibit 99.1 </p>
<p align="justify">For Canadian Distribution Only </p>
<p align="center"><b><font size="4">Lexaria Intends to Complete an Equity Financing
  of </font></b><br />
  <b><font size="4">US$300,000 </font></b></p>
<p align="justify">Kelowna, BC / July 5, 2016 / Lexaria Bioscience Corp.
  (OTCQB:LXRP) (CSE:LXX) (the &quot;Company&quot; or &quot;Lexaria&quot;) reports its intention to
  complete a non-brokered private placement financing of 5,000,000 equity units
  priced at US$0.06 (approx. CDN $0.078); each equity unit consisting of one
  common share of the Company and one non-transferable share purchase warrant,
  each whole warrant entitling the holder to purchase one additional common share
  of the Company for a period of two years from the date of issuance, at a
  purchase price of US$0.14; in order to raise gross proceeds of up to US $300,000
  (the &quot;Private Placement&quot;).</p>
<p align="justify">All funds raised of up to US$300,000 will be used to continue
  deployment and marketing of hemp based food products, for investor relations,
  for research and development including addition in vitro work, and for G&amp;A
  and general working capital. </p>
<p align="justify">The securities issued will be subject to a hold period in
  Canada of four months and one day, or for any resales into the USA under Rule
  144, six months and one day. The Private Placement will be subject to normal
  regulatory approvals.</p>
<p align="justify"><b>The securities referred to herein will not be or have not
  been registered under the United States Securities Act of 1933, as amended, and
  may not be offered or sold in the United States absent registration or an
  applicable exemption from registration requirements. </b></p>
<p align="justify"><b>About Lexaria </b></p>
<p align="justify">Lexaria Bioscience Corp. is a food sciences company focused on
  the delivery of active compounds that can behave as superfoods through its
  proprietary infusion technologies. Lexaria&#146;s technology enables higher
  bioavailability rates for CBD; THC; NSAIDs; Nicotine and other molecules than is
  possible without lipophilic enhancement technology. This can allow for lower
  overall dosing requirements and/or higher effectiveness in active molecule
  delivery. Lexaria hopes to reduce other common but less healthy ingestion
  methods such as smoking as it embraces the benefits of public health.
  www.lexariaenergy.com </p>
<p align="justify">To learn more about Lexaria Corp. visit
  www.lexariaenergy.com.</p>
<p align="justify">FOR FURTHER INFORMATION PLEASE CONTACT:</p>
<p align="justify">Lexaria Bioscience Corp.<br />
  Chris Bunka<br />
  Chairman &amp; CEO <br />
  (250) 765-6424 <br />
</p>
<hr style="PAGE-BREAK-AFTER: always" align="center" width="100%" color="black"
noshade="noshade" size="5" />
<a name="page_2" id="page_4"></a>
<p align="justify"> FORWARD-LOOKING STATEMENTS </p>
<p align="justify"> This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations,
  cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as &quot;anticipate,&quot; &quot;if,&quot;
  &quot;believe,&quot; &quot;plan,&quot; &quot;estimate,&quot; &quot;expect,&quot; &quot;intend,&quot; &quot;may,&quot; &quot;could,&quot; &quot;should,&quot; &quot;will,&quot; and other similar expressions are forward-looking statements, including but not limited to: the intention to raise up to US&#36;300,000 for various corporate
  purposes. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the
  accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Factors which could cause actual results to differ materially
  from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, the patent application and approval process and other factors
  which may be identified from time to time in the Company's public announcements and filings. There is no assurance that the medical marijuana, hemp oil sector, or alternative health businesses will provide any benefit to Lexaria, or that the Company
  will experience any growth through participation in these sectors. There is no assurance that existing capital is sufficient for the Company's needs or that it will not need to attempt to raise additional capital. There is no assurance that any
  planned corporate activity, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that any hemp oil or cannabinoid-based product will promote, assist, or maintain any beneficial human health
  conditions whatsoever. There is no assurance that the cannabinoid/lipid infusion technology will provide any increase in bioavailability to any individual person. There is no assurance that any patent application in the USA or any other nation or
  under any treaty will result in the award of an actual patent; nor that an award of any actual patent will protect against challenges from unknown third parties. There is no assurance that any of Lexaria&rsquo;s postulated uses, benefits, or
  advantages for the patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). ViPova<sup>TM</sup> products are not intended to diagnose, treat,
  cure or prevent any disease.</p>
<p align="justify"> <i>The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. </i></p>
<hr noshade="noshade" align="center" width="100%" size="5" color="black" />
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
